BEFORE THE NEVADA STATE BOARD OF PHARMACY

NEVADA STATE BOARD OF PHARMACY, ) CASE NOS. 17-038-RPH-S
)v.

ORDER

NAZALENE ZEBARI, RPH )
Certificate of Registration No. 16946 )
Respondents. )

This matter came before the Nevada State Board of Pharmacy (Board) at its regularly scheduled meeting on Wednesday, April 11, 2018, in Las Vegas, Nevada. Brett Kandt, Esq., appeared and prosecuted the case before the Board. Respondent Nazalene Zebari, R.Ph. (Zebari), Certificate of Registration 16946, appeared without counsel. The Board heard the case and, based on the evidence presented, the Board makes the following Findings of Fact, Conclusions of Law and Order.

FINDINGS OF FACT

The allegations against Zebari, as stated in the Accusation on file herein, and upon which Zebari admits and the Board makes findings of fact, are as follows:

1. Zebari was a pharmacist registered by the Board, Certificate of Registration 16946, at the time of the events herein.

2. In April 2017, a Walmart Practice Compliance (Walmart) director notified Board Staff that it terminated Zebari from her employment as a pharmacist at Walmart Pharmacy #10-4557. Walmart terminated Zebari’s employment for creating a fraudulent prescription for a non-controlled substance for personal use.

3. Zebari admitted that on June 5, 2016, she fabricated and filled a fraudulent “Telephoned Prescription” for herself for Singulair 10 mg. tablets (Prescription No. 6928848).

4. Zebari fabricated the “Telephone Prescription” by falsely documenting Dr. Koussay Zarka as the prescribing physician.
5. Zebari did not have a bona fide patient/practitioner relationship with Dr. Zarka.

6. After being apprised by Walmart of the prescription unlawfully written using his name, Dr. Zarka reviewed a copy of the prescription provided by Walmart. Dr. Zarka signed, dated and documented “not authorized” on the copy of the falsified prescription. He also signed a statement affirming that he did not authorize Prescription No. 6928848 for Zebari.

7. A Walmart Market Director confirmed to the Board Investigator that Zebari paid for the fraudulent prescription by paying the copayment and billing the prescription through her Walmart insurance plan.

8. Zebari did not ingest any of the Singulair tablets. She instead sent the medication to a relative that resides in California. The relative ingested thirty-four (34) tablets.

**CONCLUSIONS OF LAW**

Based on the forgoing findings of fact, the Board concludes as a matter of law:

9. The Board has jurisdiction over this matter and this respondent, because at the time of the events herein, Zebari was a pharmacist registered by the Board.

10. By creating a fraudulent prescription for a dangerous drug for herself as detailed herein, Zebari, violated NAC 639.945(1)(h).

11. Zebari has never been licensed as a practitioner and has never been authorized to prescribe dangerous drugs in Nevada. By prescribing a dangerous drug for herself, Zebari violated NAC 639.945(1)(h) and (k).

12. By processing a fraudulent prescription (Prescription No. 6928848) for a dangerous drug without a lawful prescription or authorization from a practitioner, and by billing that prescription to an insurance provider, Zebari violated NAC 639.945(1)(h).

13. By furnishing a dangerous drug, namely, Singulair 10 mg. tablets, to another person without a legal prescription, Zebari violated NRS 454.221 and NAC 639.945(1)(h).
14. For each of these violations, Zebari’s pharmacist registration, Certificate of Registration 16946, is subject to discipline pursuant to pursuant to NRS 639.210(1), (4), (11) and/or (12), and NRS 639.255.

ORDER

THEREFORE, THE BOARD HEREBY ORDERS AS FOLLOWS:

1. The registration of Respondent Nazalene Zebari, R.Ph., Certificate of Registration 16946, is hereby revoked.

2. Zebari may not work in any facility licensed by the Board, including a pharmacy, in any capacity unless and until she has applied to the Board for reinstatement and the Board reinstates her registration.

3. Zebari may not apply for reinstatement of her registration for a period of one year from the effective date of this Order.

4. In the event Zebari applies for reinstatement, or for any other registration or certificate with the Board, she shall appear before the Board to answer questions and give testimony regarding her application, her compliance with this Order, and the facts and circumstances underlying this matter.

5. Pursuant to NRS 639.251, this Order shall become effective 30 days after receipt by the respondent.

IT IS SO ORDERED.

Entered this 23 day of April, 2018.

Leo Basch, President
Nevada State Board of Pharmacy
BEFORE THE NEVADA STATE BOARD OF PHARMACY

NAZALENE KEMAL ZEBARI,
)
)
)
)

Petitioner,
)
)
)

CASE NO. 17-038-RPH
)
)
)

Certificate of Registration No. 16946.
)
)
)

PETITION FOR RESINSTATMENT OF CERTIFICATE OF REGISTRATION

COMES NOW Petitioner Nazalene Kemal Zebari pursuant to NRS 639.257 and hereby petitions the Nevada State Board of Pharmacy ("Board") for reinstatement of her Certificate of Registration to practice as a pharmacist based on the following.

STATEMENT OF FACTS/PROCEDURAL HISTORY

Ms. Zebari was originally licensed as a registered pharmacist by the Board in July 2006. In 2017 Ms. Zebari was employed by Walmart Pharmacy store #10-4557 in Las Vegas and had been so employed for approximately nine years. In April 2017, Ms. Zebari was terminated from her position at Walmart after it was discovered that in June 2016 she had created a fraudulent telephone prescription under the name of Dr. Koussay Zarka for Singular 10 mg tablets. Ms. Zebari filled the prescription which she subsequently sent to her sister. Ms. Zebari’s sister subsequently received a bona fide prescription for Singular from her personal physician.

The Board filed a Notice of Intended Action and Accusation on February 23, 2018 charging Ms. Zebari with four alleged violations of NRS and NAC chapters 639 regarding the creation and filling of the fraudulent prescription. Ms. Zebari filed an Answer and Notice of Defense on March 14, 2018 in which she took responsibility for her conduct. Ms. Zebari appeared before the Board on April 11, 2018 at the time of the hearing on the Accusation. Ms. Zebari again took
responsibility for her actions and apologized for her lapse in judgment. After considering the matter the Board voted to revoke Ms. Zebari’s certificate of registration to practice as a pharmacist for a minimum of one year. Ms. Zebari requested reconsideration of the Board’s decision and again appeared before the Board on June 7, 2018 after which the Board voted to uphold its previous decision to revoke Ms. Zebari’s registration for a period of at least one year.

Ms. Zebari’s registration has been revoked since April 11, 2018 and Ms. Zebari now petitions the Board for reinstatement of her certificate of registration to practice as a registered pharmacist pursuant to the Board’s order and NRS 639.257.

REQUEST FOR REINSTATEMENT

Ms. Zebari has taken full responsibility for her actions at all times since the commencement of the administrative proceedings against her and continues to do so. As Ms. Zebari presented at the time of the proceedings in 2018, she contacted Dr. Zarka by letter, and attempted by phone, to apologize for her actions, fraudulently creating a prescription under his name. (See Exhibit A)

Additionally Ms. Zebari attempted to pay Walmart for the prescription but was unable to successfully do so. Ms. Zebari also presented letters of support from colleagues, Matin Bhatt, Shelly Hausrath, Modupe Irorobede, Cherole Pils, and Gena Melnik, all of whom are licensed by the Board. (See Exhibit B)

Over the course of the preceding year since the revocation of her license, Ms. Zebari has continued to reflect on her actions and has proactively addressed her lapse of professional judgment giving rise to the action taken by the Board against her certificate of registration. While Ms. Zebari has not held fulltime work over the last year, she has engaged in volunteer work in her community and has taken almost one hundred (100) hours of additional continuing education credits to stay current in the practice of pharmacy. (See Exhibit C) Additionally, Ms. Zebari has attended almost every Board meeting held in Las Vegas since her request for rehearing was denied.
(See Exhibit D.) Through her attendance at these meetings Ms. Zebari has gained invaluable knowledge that she believes will serve her well should the Board be inclined to grant her request for reinstatement.

Should the Board grant Ms. Zebari’s request for reinstatement, Ms. Zebari is willing to comply with any requests or conditions that the Board deems advisable to place on the reinstatement of her registration. Ms. Zebari notes that she does not intend on returning to practice as a registered pharmacist on a full-time basis immediately if her registration is reinstated, but rather would like to reintegrate herself into the profession by working a few days per week.

CONCLUSION

The revocation of Ms. Zebari’s certificate of registration to practice as a pharmacist has had a profound impact on her life not only professionally, but personally. She continues to take responsibility for her profound lack of professional judgment and assures the Board that such a lapse was a one-time occurrence and that she will be diligent in ensuring that she remains in strict compliance with all professional and ethical obligations that the reinstatement of her registration would require of her. She respectfully requests that this Board reinstate her registration as a pharmacist so that she may return to practicing in her chosen profession to provide professional and compassionate assistance to patients.

Respectfully submitted this 14th day of May, 2019.

[Signature]
Lyn E. Beggs, Esq.
Attorney for Petitioner

Approved as to form and content:

[Signature]
Nazalene Kemal Zebari
EXHIBIT A
To Dr. Zarka,

I am writing this letter to offer my sincerest apologies. I am sure you aware of the situation, but I am admitting that last year, I used your name to write a prescription for myself for Singulair. I understand that what I did was ethically wrong and I took advantage of your kindness and abused my position as a pharmacist when this occurred. You have been so generous and good-hearted and betraying you this way is an insult to all the nice things you’ve done for me. I deeply regret my actions and take full responsibility for them. I don’t expect your forgiveness, but I do hope what I’ve done does not alter your opinion of the pharmacy profession. Please accept my genuine remorse.

Sincerely,

Naazlene Zebari
EXHIBIT B
4/3/2018

To the Members of the Nevada Board of Pharmacy:

I have known Nazalene Zebari professionally for over 6 years and in that time she has only shown kindness, empathy, and genuine compassion for her patients. The issue(s) that have led to her having to appear before the NV-BOP are very uncharacteristic of the person that I have known for so long. First and foremost, a lapse in judgement was made and for that there are consequences. However, if one was to carefully analyze/review her entire 12 year career as a retail pharmacist, I am quite certain that there would be no other questions regarding her character or integrity.

Again, this was certainly a lapse in both judgement and professionalism, but I do deeply believe it was a one-time lapse only and that it is truly not indicative of this person. Nazalene, is the primary financial provider for her 3 children and one of whom is set to start college shortly. This situation has impacted her tremendously and she feels a great deal of remorse and regret not only professionally but more so personally with her family. She has been very honest and accountable and I have no doubt that nothing of this nature will ever present itself again.

Throughout my career, I have been asked by various people to write recommendation letters. However, I only have written them for people I truly believe in and am not afraid to decline. When I was asked by Nazalene, I had no hesitation whatsoever. I know that good people can sometimes make uncharacteristic mistakes and I genuinely feel that she is a good person and a great pharmacist. I ask that you take all these things into account and give her the chance to keep working to both redeem herself and to continue to support her family. Thank you for your time and consideration.

Sincerely,

Matin R. Bhatt
Shelley R. Hausrath  
Casa Monica Ct  
Las Vegas, NV 89141  

April 2, 2018  

To Whom It May Concern,  

I am writing in reference to Nazalene Zebari to whom I have personally known as a friend and colleague for 15 years.  

I first met Nazalene in pharmacy school in 2003, and what impressed me the most was her kindness, warm heart, and her compassion for others. She always presents herself with levelheadedness and grace. It didn’t take me very long to know that I wanted to be friends with her. During my relationship with Nazalene, I have experienced an individual who shows up earlier than asked, works hard, and carries herself in a polite, respectable manner. In addition, she is a family-person who always puts others above herself. You can always depend on her in a time of need. She will drop everything and be by your side in a moment’s notice. I am truly honored to know such a great person that has such a strong ethical sense, a high degree of integrity and responsibility, and always maintains good moral character.  

It is my sincere hope that this letter is taken into consideration at the time of sentencing. Despite the current case, I still believe Nazalene Zebari to be an honorable individual, a valuable member of our community, and a good human being. Please do not hesitate to contact me if you should require any further information.  

Sincerely,  

[Signature]  
Shelley R. Hausrath
Providence Pharmacy
1729 E Charleston Blvd # F* Las Vegas, 89104 • P: 702-778-3072 • F: 702-778-0512

April 9, 2018

To whom it may concern,

This letter serves to verify and certify that Nazalene Zebari is a friend and coworker. I have known Nazalene for seven years and worked with her at Walmart. She also currently works at my independently owned Pharmacy per dlem. Naz came to me after she was terminated from Walmart seeking employment and was straightforward and honest about her situation. I know her to be caring, professional, and trustworthy and hard working. She continues to work for us on an as needed basis and is willing to pick up any shift to support her family. She is very helpful, great with patients and reliable. I know she can’t take back what she has done but she is a good person and loves working in the pharmacy field. I hope this letter helps in the determination of Naz’s case.

Thank you
Respectfully,

[Signature]
Pharmacy Manager
Modupe Irorobeje.
March 9, 2018

Nevada Pharmacy Board Member's:

Re: Nazalene Zebari

Dear Board Members,

My name is Cherole Pils and I have known Nazalene Zebari for the last 5 years. She has been my friend as well as a work colleague. Nazalene is truly a great pharmacist, she loves people, truly cares about their well-being and is always willing to listen to patients problems in their life unrelated to their medications. She is truly a "people person". Nazalene is very good at counseling patients, she has an amazing ability to ask the right questions to get patients to talk about themselves and find out any underlining issues that might be affecting their well-being or quality of life. She would often have patients bring in all of their medications and go over them 1 by 1 to see how they were doing on the medication and if they were having problems on specific ones. She is a very thorough and precise Pharmacist, double and triple checking Rx's that needed extra attention. She would often work extra shifts at other pharmacies to help them out when the needed arose.

Nazalene or "Naz" as her friends know her is a true and fast friend. She is fiercely loyal and also a very forgiving friend. If someone needs a sounding board for ideas she is always there offering her opinion and being your cheerleader. Naz often picked up one of the technicians that was having a lot of car problems so she could make it to work on time. She in the past had offered one of our tech's a place to stay when their house wasn't ready to be moved in yet. I hope I've given you a brief overview of Nazalene's character as well as many assets she brings to the Pharmacy profession.

Respectfully,

Cherole Pils
April 5, 2018

To whom it may concern,

My name is Gena Melnik and I am a pharmacy manager at Wal-Mart. This letter is my personal character reference for Nazalene Zebari. I have known Nazalene for 3 years and she has displayed an admirable sense of dedication to her job, where she leaves no stones unturned when it comes to tasks assigned to her. Her professional ethics has surpassed my initial expectations of her and she is one of my most dependable team player. She is able to work efficiently with or without supervision and I can rely on her to make sure the job is done. She has built good relationships with her patients that she has become the “go-to” person to help them solve their health needs.

Like any other parent of 3 beautiful kids, she has mastered the art of time management, where her responsibilities at home are not a hindrance to her excellent performance at work.

Nazalene will be a great asset to any organization. I therefore offer my highest recommendation for Nazalene to future employers who will be lucky to have her on their team.

Sincerely,

Gena Melnik
Pharmacy Manager
EXHIBIT C
Therapeutic Research Center confirms that Nazelene Zebani, Doctorate of Pharmacy license has successfully completed the courses below:

<table>
<thead>
<tr>
<th>Course Title &amp; CE Provider</th>
<th>Date Completed</th>
<th>Contact Hours</th>
<th>Requirements Met</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respecting Patients' End-of-Life Care Wishes: End-of-Life Care Planning and Palliative Pain Management</td>
<td>02/11/19</td>
<td>2.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Strategies for Communicating Effectively with Patients</td>
<td>04/02/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Tackling a Growing Problem: Childhood Obesity</td>
<td>02/26/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Disaster Preparedness &amp; Emergency Response: The Role of the Pharmacist</td>
<td>04/02/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Cultural Competence: Care of the LGBTQ Patient</td>
<td>11/08/18</td>
<td>2.00</td>
<td>General CE</td>
</tr>
<tr>
<td>The Art of Selecting &amp; Prescribing Hormonal Contraception</td>
<td>02/23/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Reproductive Health Issues for Women</td>
<td>04/09/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Travel Medicine: Passport to Staying Healthy During International Travel</td>
<td>09/17/18</td>
<td>2.00</td>
<td>General CE</td>
</tr>
<tr>
<td>A Review of DEA Requirements</td>
<td>09/29/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Safe Use of Opioids</td>
<td>02/26/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Pharmacist's Guide to Osteoporosis</td>
<td>04/02/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Resolving and Reducing Conflict and Violence in the Pharmacy</td>
<td>03/28/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Diabetes Care</td>
<td>03/28/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>The Ins and Outs of Generic Substitution</td>
<td>02/26/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>HIV/AIDS Prevention and Management</td>
<td>04/02/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Pharmacy Leadership: Developing Leadership Skills</td>
<td>03/28/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Controlled Substances in West Virginia: Best Practices in Prescribing and Preventing Diversion</td>
<td>01/17/19</td>
<td>3.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Preventing Medication Errors</td>
<td>01/17/19</td>
<td>2.00</td>
<td>General CE</td>
</tr>
</tbody>
</table>
Managing Up: Improving Work Relationships
ACPE#: JA0006454-0000-18-075-H04-P
c1690b0-2c28-449d-9b90-7894a323f13c (printed previously)
03/28/19 1.00 General CE

Controlled Substances: Preventing Diversion and Promoting Patient Safety with Opioids
ACPE#: JA0006454-0000-18-042-H05-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/17/19 2.00 General CE

Empathy in the Pharmacy Setting: Strategies for Providing Empathetic Care
ACPE#: JA0006454-0000-18-308-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
03/28/19 1.00 General CE

Controlled Substance Prescriptions: Balancing Access and Diversion Prevention
ACPE#: JA0006454-0000-18-218-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/17/19 2.00 General CE

Naloxone Rescue Therapy for Opioid Overdose
ACPE#: JA0006454-0000-18-213-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
10/11/18 2.00 General CE

Medication Adherence: What You Need to Know
ACPE#: JA0006454-0000-18-223-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
02/11/19 1.00 General CE

Drug Therapy Review for HIV/AIDS
ACPE#: JA0006454-0000-18-210-H02-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
09/28/18 2.00 General CE

Federal Pharmacy Law
ACPE#: JA0006454-0000-18-314-H03-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
10/09/18 1.00 General CE

Attention-Deficit / Hyperactivity Disorder; ADHD
ACPE#: JA0006454-0000-18-214-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
04/09/19 1.00 General CE

Acne
ACPE#: JA0006454-0000-18-337-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
04/02/19 1.00 General CE

Embracing Cultural Competence and Improving Cultural Communications
ACPE#: JA0006454-0000-18-313-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
04/09/19 1.00 General CE

Managing Chronic Opioid Patients in the Community Pharmacy Setting
ACPE#: JA0006454-0000-18-225-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
02/11/19 1.00 General CE

Burn Injury and the Impact on Pharmacokinetics
ACPE#: JA0006454-0000-18-232-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
04/02/19 1.00 General CE

Travel Medicine: Passport to Healthy and Safe International Travel
ACPE#: JA0006454-0000-18-246-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/17/19 2.00 General CE

A Guide to the 2018-2019 Influenza Season Recommendations
ACPE#: JA0006454-0000-18-243-H06-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/17/19 1.00 Immunization CE

Influenza Vaccination for Special Populations
ACPE#: JA0006454-0000-18-244-H06-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/17/19 1.00 Immunization CE

The Pharmacy Team's Role in Ensuring Appropriate Use of Live Vaccines
ACPE#: JA0006454-0000-18-327-H06-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
01/09/19 1.00 Immunization CE

Recognizing and Reporting Child Abuse in Pennsylvania
ACPE#: JA0006454-0000-18-326-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
02/11/19 2.00 General CE

The Pharmacy Team's Role in the Management of Dementia
ACPE#: JA0006454-0000-18-328-H01-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
04/02/19 1.00 General CE

Motivational Interviewing to Promote Change
ACPE#: JA0006454-0000-18-247-H04-P
cb1e9fb0-2c28-449d-9b90-7894a323f13c (printed previously)
03/28/19 1.00 General CE
<table>
<thead>
<tr>
<th>Topic</th>
<th>Date</th>
<th>Hours</th>
<th>CE Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suicide Assessment, Prevention, and Intervention</td>
<td>01/17/19</td>
<td>3.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Counseling Patients with Type 2 Diabetes</td>
<td>04/09/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>New Drugs Available in 2018</td>
<td>02/26/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care October 2017</td>
<td>08/16/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care November 2017</td>
<td>08/24/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care December 2017</td>
<td>08/29/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care January 2018</td>
<td>08/29/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care February 2018</td>
<td>08/29/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care March 2018</td>
<td>01/17/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care April 2018</td>
<td>01/17/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care May 2018</td>
<td>01/17/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care June 2018</td>
<td>01/17/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care July 2018</td>
<td>02/11/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care August 2018</td>
<td>09/17/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care September 2018</td>
<td>09/17/18</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care October 2018</td>
<td>02/11/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care November 2018</td>
<td>01/08/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>Emerging Developments in Drug Therapy and Implementation into Patient Care December 2018</td>
<td>01/08/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
</tbody>
</table>
Pharmacist's Letter CE-in-the-Letter

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/06/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>02/11/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>03/19/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
<tr>
<td>04/02/19</td>
<td>1.00</td>
<td>General CE</td>
</tr>
</tbody>
</table>

and is awarded 74.00 total Contact Hours

In support of improving patient care, Therapeutic Research Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Tammie Armeni, RPh, PharmD
April 26, 2019

US-licensed Pharmacists/Technicians: This certificate is supplied as a courtesy to our participants. Official Statements of Credit are only available through CPE Monitor.

These courses are sponsored by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219
TEL: (209) 472-2240 FAX: (209) 472-2249

Print

Close Window
Certificate of Achievement

Presented to:
Nazalene Zebari

by Pharmacy Ethics Education, and Resources (PEER)

Test name: Priority of Pharmacy Ethics in Healthcare-Module 1
Score: 75% (9 out of 12)

Priority of Pharmacy Ethics in Healthcare Online Course, a knowledge-based course, has been approved for 1 contact hour (0.1 CEU) of continuing education credit obtained in the home study with ACPE Universal Activity Numbers 0201-9999-16-057-H04 P/T.

Tue 10th Apr 2018

The American College of Apothecaries (ACA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. All sessions carrying the ACPE program number are approved for continuing education credit.
Certificate of Achievement

Presented to:
Nazalene Zebari

by Pharmacy Ethics Education, and Resources (PEER)

Test name: Evolution of Healthcare Ethics-Module 2
Score: 90% (9 out of 10)

Evolution of Healthcare Ethics Online Course, a knowledge-based course, has been approved for 1 contact hour (0.1 CEU) of continuing education credit obtained in the home study with ACPE Universal Activity Numbers 0201-9999-16-058-H04 P/V/T.

Wed 10th Apr 2019
STATEMENT OF CREDIT

Nazalene Zebari

CPE Monitor ID: 135134

Pharmacy Law vs. Pharmacy Ethics

Accreditation Number: 0798-0000-17-167-H03-P
Activity Type: Knowledge
Date Completed: Tuesday, April 10, 2018

This activity has been approved for 1 contact hour(s) of continuing education for Pharmacists.

PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Kevin Hope, RPh
Continuing Education Administrator

Signed and issued on: 4/10/2018

This Statement of Credit will be retained online by freeCE for a minimum of five (5) years.

PharmCon | 1404-A Main Street | Conway, SC 29526 | (843) 488-5550 | www.freece.com
Certificate of Completion

The

California Board of Pharmacy

2018 Pharmacy Law Continuing Education Course

1 Hour tutorial

Print and keep this certificate for your records

<table>
<thead>
<tr>
<th>Enter Your Name</th>
<th>Nazalene Zeba</th>
</tr>
</thead>
<tbody>
<tr>
<td>Select License Type</td>
<td>Pharmacist / Nevada</td>
</tr>
<tr>
<td>Enter License #</td>
<td>110940</td>
</tr>
<tr>
<td>Enter Your Email</td>
<td><a href="mailto:nazalee.zeba@yahoo.com">nazalee.zeba@yahoo.com</a></td>
</tr>
</tbody>
</table>
1/19/2019

Introduction to Homeopathic Medicine for the Pharmacy Professional

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,
Power-Pak C.E.
1/19/2019

Beyond Fiber and Laxatives: Advising Patients with Chronic and Refractory Constipation-Article

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,
Power-Pak C.E.
1/19/2019

How Specialty Pharmacists Can Enhance Patient-Driven Care in Multiple Sclerosis

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,
Power-Pak C.E.
1/18/2019

Itching to Improve Allergic Rhinitis Management? Tips for Patient Care

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,
Power-Pak C.E.
1/18/2019

Caring For Cold Sores In The Community Pharmacy

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4408.

Sincerely,
Power-Pak C.E.
1/18/2019

Targeting Underserved Populations for Diabetes Screening and Education

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP's CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://rabb.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,

Power-Pak C.E.
1/18/2019

Acetaminophen-Induced Hepatotoxicity: The Pharmacist's Role in Prevention and Treatment

Dear Nazâlêne Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP's CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP's CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4406.

Sincerely,

Power-Pak C.E.
1/18/2019

Caring for Contact Lenses: A Guide for the Pharmacist

Dear Nazalene Zebari

You have successfully completed the post-test and evaluation for the above-named activity. A record of your participation and verification of credit will be maintained with the accredited provider and a record of successful completion of this activity will be submitted to ACPE/NABP’s CPE Monitor. You may look for your statement of credit to appear in your CPE Monitor account in approximately 1 week.

Only learners who provided valid NABP e-Profile ID numbers and PIN numbers (month and day of birth) in their registration information will be submitted to ACPE/NABP’s CPE Monitor for official record of credit. Pharmacy learners who do not provide this information will not be eligible to receive credit.

You can access your CPE Monitor Account through the NABP website link: https://nabp.pharmacy/cpe-monitor-service/ or contact NABP Customer Service at (847) 391-4408.

Sincerely,
Power-Pak C.E.
EXHIBIT D
NEVADA STATE BOARD OF PHARMACY
CERTIFICATE OF CONTINUING EDUCATION

DATED JUL 18 2018

3 ACCREDITED HOURS OF CE WAS EARNED.
1 ACCREDITED HOUR OF LAW CE WAS EARNED.

WAS IN ATTENDANCE AT
THE NEVADA STATE BOARD OF PHARMACY MEETING HELD IN LAS VEGAS,

LARRY PENSON, PHARM.D.

You must maintain this certificate and only provide if audited.

The board of pharmacy office does not have a copy and can not provide a

COPY IF YOU ARE AUDITED.
You must maintain this certificate and only provide a copy if audited.

Larry Pinson, PharmD

NEVADA STATE BOARD OF PHARMACY

CERTIFICATE OF CONTINUING EDUCATION

DATED Oct 11, 2018

The Nevada State Board of Pharmacy Meeting held in Las Vegas;

1 Accredited Hour of Law CE Was Earned.

3 Accredited Hours of CE Was Earned.

Scanned with CamScanner
Executive Secretary
J. David West, R.Ph.

1

3

Accredited hour of Law was earned.

Accredited hours of CE was earned.

Nevada State Board of Pharmacy meeting held in Las Vegas, Nevada.

Was in attendance at the

Date: Jan 16, 2019

Certificate of Continuing Education
Nevada State Board of Pharmacy
Nevada State Board of Pharmacy
Certificate of Continuing Education

Date: JAN 7 2019

Zohri was in attendance at the Nevada State Board of Pharmacy meeting held in Las Vegas, Nevada.

3 accredited hours of CE was earned.

J. David Wuest, R.Ph.
Executive Secretary

**You must maintain this certificate and only provide a copy if audited.**

The Board of Pharmacy office does not have a copy and cannot provide a copy if you are audited.
The Board of Pharmacy office does not have a copy and cannot provide a copy if you are unable.

You must maintain this certificate and only provide a copy if requested.

Executive Secretary
J. David West, R.Ph.

Accredited hours of CE was earned:

1  
3

Nevada State Board of Pharmacy meeting held in Las Vegas, Nevada.

Nagele Zebel was in attendance at the

Date: APR 10 2019

Certificate of Continuing Education

Nevada State Board of Pharmacy
The Board of Pharmacy office does not have a copy and cannot provide a copy if you are audited.

J. David Wuest, R.Ph.
Executive Secretary

3 accredited hours of CE were earned.

1 accredited hour of law was earned.

Nevada State Board of Pharmacy was in attendance at the Nevada State Board of Pharmacy meeting held in Las Vegas, Nevada.

Date: APR 1, 2019

Scanned with CamScanner